Segall Bryant & Hamill LLC Acquires New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Segall Bryant & Hamill LLC purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 25,377 shares of the specialty pharmaceutical company's stock, valued at approximately $791,000.

Other institutional investors have also modified their holdings of the company. Renaissance Technologies LLC increased its stake in shares of Supernus Pharmaceuticals by 26.4% during the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company's stock worth $45,077,000 after buying an additional 351,900 shares during the period. Bank of Montreal Can increased its position in shares of Supernus Pharmaceuticals by 1,508.0% in the 2nd quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company's stock valued at $3,287,000 after purchasing an additional 109,088 shares during the last quarter. Candriam S.C.A. acquired a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $3,795,000. Stephens Investment Management Group LLC grew its stake in shares of Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company's stock worth $60,246,000 after purchasing an additional 33,710 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in Supernus Pharmaceuticals by 369.1% in the second quarter. American Century Companies Inc. now owns 501,658 shares of the specialty pharmaceutical company's stock valued at $13,419,000 after buying an additional 394,728 shares in the last quarter.

Analysts Set New Price Targets

SUPN has been the subject of several recent analyst reports. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, August 7th. Piper Sandler reiterated a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, Cowen reaffirmed a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock traded down $0.12 during midday trading on Monday, reaching $36.10. 283,774 shares of the company traded hands, compared to its average volume of 445,052. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.37. The firm has a market cap of $1.99 billion, a PE ratio of 33.74 and a beta of 0.86. The firm's 50 day simple moving average is $33.81 and its two-hundred day simple moving average is $31.14.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company had revenue of $175.70 million for the quarter, compared to analysts' expectations of $157.35 million. During the same period last year, the company earned ($0.29) EPS. The firm's revenue for the quarter was up 14.2% compared to the same quarter last year. As a group, research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Georges Gemayel sold 14,213 shares of the firm's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the transaction, the director now directly owns 13,315 shares in the company, valued at $487,595.30. This trade represents a 51.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of the firm's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the completion of the transaction, the senior vice president now directly owns 8,200 shares in the company, valued at $303,236. This represents a 64.66 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 154,213 shares of company stock worth $5,660,180. 9.30% of the stock is currently owned by company insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.